Is Sana Biotechnology Stock a Good Investment?
Sana Biotechnology Investment Advice | SANA |
- Examine Sana Biotechnology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sana Biotechnology's leadership team and their track record. Good management can help Sana Biotechnology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Sana Biotechnology's business and its evolving consumer preferences.
- Compare Sana Biotechnology's performance and market position to its competitors. Analyze how Sana Biotechnology is positioned in terms of product offerings, innovation, and market share.
- Check if Sana Biotechnology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sana Biotechnology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sana Biotechnology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sana Biotechnology is a good investment.
Sell | Buy |
Sell
Market Performance | Insignificant | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Sana Biotechnology Stock
Researching Sana Biotechnology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 94.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.98. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sana Biotechnology recorded a loss per share of 1.4. The entity had not issued any dividends in recent years.
To determine if Sana Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sana Biotechnology's research are outlined below:
| Sana Biotechnology is way too risky over 90 days horizon | |
| Sana Biotechnology appears to be risky and price may revert if volatility continues | |
| Sana Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (283.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Sana Biotechnology currently holds about 484.8 M in cash with (253.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.57. | |
| Sana Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: SANA Gears Up to Report Q4 Earnings Whats in the Cards |
Sana Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sana Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sana Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Sana Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Sana Biotechnology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.28 | -0.32 | -0.04 | 14 | ||
2022-11-02 | 2022-09-30 | -0.53 | -0.45 | 0.08 | 15 | ||
2022-08-04 | 2022-06-30 | -0.51 | -0.39 | 0.12 | 23 | ||
2023-03-16 | 2022-12-31 | -0.51 | -0.38 | 0.13 | 25 | ||
2021-08-04 | 2021-06-30 | -0.45 | -0.32 | 0.13 | 28 | ||
2021-05-05 | 2021-03-31 | -0.58 | -0.45 | 0.13 | 22 | ||
2023-08-03 | 2023-06-30 | -0.43 | -0.59 | -0.16 | 37 | ||
2023-11-08 | 2023-09-30 | -0.45 | 0.02 | 0.47 | 104 |
Sana Biotechnology Target Price Consensus
Sana target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Sana Biotechnology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Sana analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Sana stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Sana Biotechnology, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSana Biotechnology Target Price Projection
Sana Biotechnology's current and average target prices are 2.68 and 9.80, respectively. The current price of Sana Biotechnology is the price at which Sana Biotechnology is currently trading. On the other hand, Sana Biotechnology's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Sana Biotechnology Market Quote on 26th of February 2025
Target Price
Analyst Consensus On Sana Biotechnology Target Price
Sana Biotechnology Analyst Ratings
Sana Biotechnology's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Sana Biotechnology stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Sana Biotechnology's financials, market performance, and future outlook by experienced professionals. Sana Biotechnology's historical ratings below, therefore, can serve as a valuable tool for investors.Know Sana Biotechnology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sana Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sana Biotechnology backward and forwards among themselves. Sana Biotechnology's institutional investor refers to the entity that pools money to purchase Sana Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alphabet Inc | 2024-12-31 | 2.8 M | Baker Bros Advisors Lp | 2024-12-31 | 2.4 M | Integral Health Asset Management, Llc | 2024-12-31 | 2 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.9 M | Jpmorgan Chase & Co | 2024-09-30 | 1.8 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.6 M | Boxer Capital Llc | 2024-09-30 | 1.5 M | Northern Trust Corp | 2024-12-31 | 1.2 M | Ci Private Wealth Llc | 2024-12-31 | 1.2 M | Fmr Inc | 2024-12-31 | 33.5 M | Flagship Ventures Management, Inc. | 2024-12-31 | 25 M |
Sana Biotechnology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 578.27 M.Market Cap |
|
Sana Biotechnology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.89) | (0.94) | |
| Return On Capital Employed | (0.75) | (0.79) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.13) | (1.08) |
Determining Sana Biotechnology's profitability involves analyzing its financial statements and using various financial metrics to determine if Sana Biotechnology is a good buy. For example, gross profit margin measures Sana Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sana Biotechnology's profitability and make more informed investment decisions.
Please note, the presentation of Sana Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sana Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sana Biotechnology's management manipulating its earnings.
Evaluate Sana Biotechnology's management efficiency
Sana Biotechnology has return on total asset (ROA) of (0.3115) % which means that it has lost $0.3115 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.929) %, meaning that it created substantial loss on money invested by shareholders. Sana Biotechnology's management efficiency ratios could be used to measure how well Sana Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2025, Return On Tangible Assets is expected to decline to -0.94. In addition to that, Return On Capital Employed is expected to decline to -0.79. At present, Sana Biotechnology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 361.6 M, whereas Non Current Assets Total are forecasted to decline to about 352.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.33 | 0.72 | |
| Tangible Book Value Per Share | 0.41 | 0.43 | |
| Enterprise Value Over EBITDA | (2.73) | (2.86) | |
| Price Book Value Ratio | 2.48 | 2.61 | |
| Enterprise Value Multiple | (2.73) | (2.86) | |
| Price Fair Value | 2.48 | 2.61 | |
| Enterprise Value | 7.2 B | 7.1 B |
Leadership effectiveness at Sana Biotechnology is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 1.604 |
Basic technical analysis of Sana Stock
As of the 26th of February, Sana Biotechnology has the Semi Deviation of 6.39, coefficient of variation of 1529.08, and Risk Adjusted Performance of 0.0577. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sana Biotechnology, as well as the relationship between them.Sana Biotechnology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sana Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sana Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sana Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sana Biotechnology's Outstanding Corporate Bonds
Sana Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sana Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sana bonds can be classified according to their maturity, which is the date when Sana Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Sana Biotechnology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sana Biotechnology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0577 | |||
| Market Risk Adjusted Performance | 0.4966 | |||
| Mean Deviation | 8.05 | |||
| Semi Deviation | 6.39 | |||
| Downside Deviation | 7.2 | |||
| Coefficient Of Variation | 1529.08 | |||
| Standard Deviation | 21.05 | |||
| Variance | 443.3 | |||
| Information Ratio | 0.0647 | |||
| Jensen Alpha | 1.35 | |||
| Total Risk Alpha | 1.23 | |||
| Sortino Ratio | 0.1892 | |||
| Treynor Ratio | 0.4866 | |||
| Maximum Drawdown | 176.41 | |||
| Value At Risk | (11.88) | |||
| Potential Upside | 12.46 | |||
| Downside Variance | 51.8 | |||
| Semi Variance | 40.89 | |||
| Expected Short fall | (11.15) | |||
| Skewness | 6.84 | |||
| Kurtosis | 52.09 |
| Risk Adjusted Performance | 0.0577 | |||
| Market Risk Adjusted Performance | 0.4966 | |||
| Mean Deviation | 8.05 | |||
| Semi Deviation | 6.39 | |||
| Downside Deviation | 7.2 | |||
| Coefficient Of Variation | 1529.08 | |||
| Standard Deviation | 21.05 | |||
| Variance | 443.3 | |||
| Information Ratio | 0.0647 | |||
| Jensen Alpha | 1.35 | |||
| Total Risk Alpha | 1.23 | |||
| Sortino Ratio | 0.1892 | |||
| Treynor Ratio | 0.4866 | |||
| Maximum Drawdown | 176.41 | |||
| Value At Risk | (11.88) | |||
| Potential Upside | 12.46 | |||
| Downside Variance | 51.8 | |||
| Semi Variance | 40.89 | |||
| Expected Short fall | (11.15) | |||
| Skewness | 6.84 | |||
| Kurtosis | 52.09 |
Consider Sana Biotechnology's intraday indicators
Sana Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sana Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Sana Biotechnology Corporate Filings
| 31st of January 2025 Other Reports | ViewVerify | |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 10th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 21st of November 2024 Other Reports | ViewVerify |
Sana Stock media impact
Far too much social signal, news, headlines, and media speculation about Sana Biotechnology that are available to investors today. That information is available publicly through Sana media outlets and privately through word of mouth or via Sana internal channels. However, regardless of the origin, that massive amount of Sana data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sana Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sana Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sana Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sana Biotechnology alpha.
Sana Biotechnology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sana Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Top Midday Gainers
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Sana Biotechnology Historical Investor Sentiment
Investor biases related to Sana Biotechnology's public news can be used to forecast risks associated with an investment in Sana. The trend in average sentiment can be used to explain how an investor holding Sana can time the market purely based on public headlines and social activities around Sana Biotechnology. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Sana Biotechnology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Sana Biotechnology and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Sana Biotechnology news discussions. The higher the estimate score, the more favorable the investor's outlook on Sana Biotechnology.
Sana Biotechnology Maximum Pain Price Across April 17th 2025 Option Contracts
Sana Biotechnology's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Sana Biotechnology close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Sana Biotechnology's options.
Sana Biotechnology Corporate Management
| Sunil MD | Head VP | Profile | |
| Christian MBA | Executive Officer | Profile | |
| Shanna Peek | Sr Operations | Profile | |
| Richard Mulligan | Executive Research | Profile | |
| Sonja MD | Senior Platform | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Sana Biotechnology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.